Pharma Focus Asia

Icagen and Omdana Therapeutics Announce Collaboration to Pursue Therapies for Patients with Pulmonary Hypertension

Wednesday, June 21, 2017

Icagen, Inc. and Omdana Therapeutics, Inc. announced a collaboration to help advance the discovery of novel medicines for disorders related to tissue homeostasis and vascular remodeling such as pulmonary hypertension.  Omdana, a company co-founded by pharma veterans Drs. Christopher VanDeusen and Steve Ledbetter, will partner with Icagen as an integrated drug discovery team with the goal of developing high-quality, advanced leads ready for clinical trials.  

"Omdana is venturing into this program because therapies are needed that can truly address underlying tissue and vascular remodeling," said Dr. VanDeusen. "Icagen represents an ideal partner for moving from target to lead in a timely manner.  Icagen's scientific team and their breadth of experience and capabilities are second to none."

"Icagen is pleased to partner with Omdana Therapeutics on this important project," said Richie Cunningham, President & CEO of Icagen.  "The Omdana co-founders also bring years of pharma experience and know-how for making successful drug candidates.  Together we believe that we can make a nimble team of drug discoverers ready to advance compounds at a pace that we expect will beat the industry average."

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024